It's worth checking!
SX-682 Plus Enzalutamide in Men with ... - Fight Prostate Ca...
SX-682 Plus Enzalutamide in Men with Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer: Phase 1/2 trial recruiting
Written by
Maxone73
To view profiles and participate in discussions please or .
Read more about...
2 Replies
•
Hi Max. Very interesting initiative, will try to monitor progress. Was unaware that only 35% of mCRPC cases who fail Zytiga can successfully move to Xtandi. Thanks for sending.
Locations
UCSF accepting new patients
San Francisco California 94143 United States
University of California, Los Angeles accepting new patients
Los Angeles California 90095 United States
Not what you're looking for?
You may also like...
Phase 2 trial: adaptive ADT for metastatic castration sensitive prostate cancer
The H. Lee Moffitt Cancer Center is advancing prostate cancer treatment with a Phase 2 trial...
Phase 3 trial: 177Lu-DOTA-rosopatamab (TLX591) for patients with PSMA expressing metastatic castration-resistant prostate cancer
Doctors in Perth, Australia are leading a Phase 3 clinical trial called ProstACT GLOBAL, which is...
Estimating the Number of Men Living with Metastatic Prostate Cancer in the United States
New study below [1].
The U.S. PCa estimates for 2023: 288,300 new cases & 34,700 deaths.
For...
Inverse Regulation of DHT Synthesis Enzymes 5α-Reductase Types 1 & 2 by the Androgen Receptor in Prostate Cancer - Endocrinology, April 2017
This 2017 research paper describes the inverse enzyme conversion that takes place in the conversion...
